Characteristics of studies comparing pregnancy outcome in women with SCD (genotype unspecified) against women with no sickle cell disease
| . | Country . | GNI $ (year) . | Duration of study . | Unspecified SCD women, N (N pregnancies) . | No SCD women, N (N pregnancies) . | Transfusion details . | Quality of reporting (NOS) of 9 . |
|---|---|---|---|---|---|---|---|
| Total N | 24 794 (24 969) | 26 147 824 (26 181 224) | |||||
| First author and year of publication | |||||||
| Alayed 201324 | Canada | 42 530 (2012) | 1999-2008 | 4262 (4262) | 8 817 059 (8 817 059) | No data on transfusion for study population | 6 |
| Al Mulhim 200025 | Saudi Arabia | 30 160 (2011) | 1997-1998 | 61 (61) | 84 (84) | 45.9% SCD (on clinical indications) vs 1.1% controls | 5 |
| Barfield 201026 | United States | 52 610 (2012) | 1998-2006 | 488 (663) | 83 877 (115 160) | No data on transfusion for study population | 5 |
| Boulet 201327 | United States | 52 610 (2012) | 2004-2010 | 1526 (1526) | 333 822 (333 822) | 12.9% SCD vs 1.2% controls (indication not given) | 3 |
| Muganyizi 201328 | Tanzania | 1,560 (2012) | 1999-2011 | 149 (149) | 155 207 (157 324) | No data on transfusion for study population | 5 |
| Natu 201429 | India | 3,910 (2012) | 2012 | 25 (25) | 500 (500) | 60.0% SCD (prophylactic) and 40.0% (on clinical indications) vs 0% controls | 4 |
| Rajab 200630 | Bahrain | 18 910 (2010) | 1998-2002 | 331 (331) | 331 (331) | 48.9% SCD (top-up transfusion); 3% SCD (exchange transfusion) for prophylaxis | 6 |
| Villers 200831 | United States | 52 610 (2012) | 2000-2003 | 17 952 (17 952) | 16 756,944 (16 756,944) | No raw data on transfusion for study population | 4 |
| . | Country . | GNI $ (year) . | Duration of study . | Unspecified SCD women, N (N pregnancies) . | No SCD women, N (N pregnancies) . | Transfusion details . | Quality of reporting (NOS) of 9 . |
|---|---|---|---|---|---|---|---|
| Total N | 24 794 (24 969) | 26 147 824 (26 181 224) | |||||
| First author and year of publication | |||||||
| Alayed 201324 | Canada | 42 530 (2012) | 1999-2008 | 4262 (4262) | 8 817 059 (8 817 059) | No data on transfusion for study population | 6 |
| Al Mulhim 200025 | Saudi Arabia | 30 160 (2011) | 1997-1998 | 61 (61) | 84 (84) | 45.9% SCD (on clinical indications) vs 1.1% controls | 5 |
| Barfield 201026 | United States | 52 610 (2012) | 1998-2006 | 488 (663) | 83 877 (115 160) | No data on transfusion for study population | 5 |
| Boulet 201327 | United States | 52 610 (2012) | 2004-2010 | 1526 (1526) | 333 822 (333 822) | 12.9% SCD vs 1.2% controls (indication not given) | 3 |
| Muganyizi 201328 | Tanzania | 1,560 (2012) | 1999-2011 | 149 (149) | 155 207 (157 324) | No data on transfusion for study population | 5 |
| Natu 201429 | India | 3,910 (2012) | 2012 | 25 (25) | 500 (500) | 60.0% SCD (prophylactic) and 40.0% (on clinical indications) vs 0% controls | 4 |
| Rajab 200630 | Bahrain | 18 910 (2010) | 1998-2002 | 331 (331) | 331 (331) | 48.9% SCD (top-up transfusion); 3% SCD (exchange transfusion) for prophylaxis | 6 |
| Villers 200831 | United States | 52 610 (2012) | 2000-2003 | 17 952 (17 952) | 16 756,944 (16 756,944) | No raw data on transfusion for study population | 4 |
All studies were historical cohort studies of pregnancy.